modelGlimepirideAndRosiglitaz
Extends from Pharmacolibrary.Drugs.ATC.A.A10BD04.
Information
| name: | GlimepirideAndRosiglitazone | |
| ATC code: | A10BD04 | route: | oral |
| compartments: | 1 | |
| dosage: | 4 | mg |
| volume of distribution: | 10 | L |
| clearance: | 0.24 | L/h |
| other parameters in model implementation | ||
Glimepiride and rosiglitazone is a fixed-dose combination of an oral sulfonylurea (glimepiride), which stimulates insulin secretion from pancreatic beta cells, and a thiazolidinedione (rosiglitazone), which improves insulin sensitivity in peripheral tissues. The combination is used for the management of type 2 diabetes mellitus in adults. The combination is approved for use in several countries, although rosiglitazone's approval status may vary due to cardiovascular safety concerns.
Pharmacokinetics
Estimated typical pharmacokinetic parameters for healthy adult subjects; individual PK studies generally report on monotherapy, as no published population PK model for the fixed-dose combination was identified.
References
Kirchheiner, J, et al., & Brockmöller, J (2005). Effect of genetic polymorphisms in cytochrome p450 (CYP) 2C9 and CYP2C8 on the pharmacokinetics of oral antidiabetic drugs: clinical relevance. Clinical pharmacokinetics 44(12) 1209–1225. DOI:10.2165/00003088-200544120-00002 PUBMED:https://pubmed.ncbi.nlm.nih.gov/16372821
Vaidyanathan, J, et al., & Sahajwalla, CG (2012). Type 2 diabetes in pediatrics and adults: thoughts from a clinical pharmacology perspective. Journal of pharmaceutical sciences 101(5) 1659–1671. DOI:10.1002/jps.23085 PUBMED:https://pubmed.ncbi.nlm.nih.gov/22383396
Plosker, GL, & Figgitt, DP (2004). Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus. PharmacoEconomics 22(6) 389–411. DOI:10.2165/00019053-200422060-00005 PUBMED:https://pubmed.ncbi.nlm.nih.gov/15099124
Parameters
| Type | Name | Default | Description |
|---|---|---|---|
| Modelica.Units.SI.Mass | weight (from PK_1C) | 75 | patient weight (kg) |
| Modelica.Units.SI.SpecificVolume | VdPerKg (from PK_1C) | 0.9 | Volume of distribution (L/kg) |
| Modelica.Units.SI.MassFraction | F (from PK_1C) | 0.8 | bioavailiability (0-1) |
| Pharmacolibrary.Types.Clearance | Cl (from PK_1C) | 20 | clearance |
| Modelica.Units.SI.Time | adminTime (from PK_1C) | 60 | first administration time (s) |
| Modelica.Units.SI.Time | adminDuration (from PK_1C) | 600 | administration duration (s) |
| Modelica.Units.SI.Time | adminPeriod (from PK_1C) | 8*60*60 | period of administration (default 8 hours)(s) |
| Pharmacolibrary.Types.Mass | adminMass (from PK_1C) | 1000 | administration mass (mg) |
| Integer | adminCount (from PK_1C) | 8 | number of dose administered (1) |
| Pharmacolibrary.Types.Volume | Vd (from PK_1C) | VdPerKg*weight | Volume of distribution (m3) |
| Pharmacolibrary.Types.MassConcentration | Cmin (from PK_1C) | 0.004 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Cmax (from PK_1C) | 0.008 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Ctox_peak (from PK_1C) | 0.012 | toxicity peak level |
| Pharmacolibrary.Types.MassConcentration | Ctox_trough (from PK_1C) | 0.006 | toxicity trough level |
| Pharmacolibrary.Types.TransferRate | ka (from PK_1C_enteral) | 0.016666666666666666 | first order absorption rate |
| Modelica.Units.SI.Time | Tlag (from PK_1C_enteral) | 600 | delay between oral administration and absorption (default 10min) |
Connectors
| Type | Name | Default | Description |
|---|---|---|---|
| Types.ConcentrationOutput | C_central (from PK_1C) | ||
| Interfaces.ConcentrationPort_b | centralCPort (from PK_1C) |
Components
| Type | Name | Default | Description |
|---|---|---|---|
| Pharmacokinetic.NoPerfusedTissueCompartment | central (from PK_1C) | ||
| Pharmacokinetic.ClearanceDrivenElimination | elim (from PK_1C) | ||
| Sources.PeriodicDose | periodicDose (from PK_1C) | ||
| Modelica.Units.SI.Time | t1_2 (from PK_1C) | elimination half-life |
Revisions
- 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)